Method of kidney treatment
First Claim
Patent Images
1. A method of treating renal colic in a subject, comprising:
- administering to the subject in need thereof, a therapeutic effective amount of a compound of the formula;
wherein R1 and R2, independently, are hydrogen or a C1-C6 linear or branched alkyl optionally interrupted by a carbonyl;
R3 is a C1-C8 alkyl substituted by one or more moieties selected from the group consisting of hydroxyl, amino, mercapto, dioxolan, carbonyl and mixtures thereof; and
R4 is hydrogen;
a substituted or unsubstituted aromatic member selected from the group consisting of phenyl, biphenyl, benzyl, and furyl, wherein the substituent is selected from the group consisting of C1-C4 alkyl, C1-C4 haloalkyl, C1-C4 alkoxy, C1-C4 alkylthio, halo and nitro;
or a cycloalkyl selected from the group consisting of cyclohexyl and cyclopentyl;
or a pharmaceutically acceptable acid addition salt thereof, in a unit dosage form.
1 Assignment
0 Petitions
Accused Products
Abstract
A method of treating and/or preventing renal dysfunction in a patient, such as renal colic or contrast nephropathy by administering to a patient, a compound of the formula:
is described herein. Administration of dyphylline in a sustained release oral dosage form is preferred.
33 Citations
20 Claims
-
1. A method of treating renal colic in a subject, comprising:
- administering to the subject in need thereof, a therapeutic effective amount of a compound of the formula;
wherein R1 and R2, independently, are hydrogen or a C1-C6 linear or branched alkyl optionally interrupted by a carbonyl;
R3 is a C1-C8 alkyl substituted by one or more moieties selected from the group consisting of hydroxyl, amino, mercapto, dioxolan, carbonyl and mixtures thereof; and
R4 is hydrogen;
a substituted or unsubstituted aromatic member selected from the group consisting of phenyl, biphenyl, benzyl, and furyl, wherein the substituent is selected from the group consisting of C1-C4 alkyl, C1-C4 haloalkyl, C1-C4 alkoxy, C1-C4 alkylthio, halo and nitro;
or a cycloalkyl selected from the group consisting of cyclohexyl and cyclopentyl;
ora pharmaceutically acceptable acid addition salt thereof, in a unit dosage form. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10)
- administering to the subject in need thereof, a therapeutic effective amount of a compound of the formula;
-
11. A method of preventing contrast nephropathy in a subject, comprising:
- administering to the subject in need thereof, a prophylactically effective amount of a compound of the formula;
wherein R1 and R2, independently, are hydrogen or a C1-C6 linear or branched alkyl optionally interrupted by a carbonyl;
R3 is a C1-C8 alkyl substituted by one or more moieties selected from the group consisting of hydroxyl, amino, mercapto, dioxolan, carbonyl and mixtures thereof; and
R4 is hydrogen;
a substituted or unsubstituted aromatic member selected from the group consisting of phenyl, biphenyl, benzyl, and furyl, wherein the substituent is selected from the group consisting of C1-C4 alkyl, C1-C4 haloalkyl, C1-C4 alkoxy, C1-C4 alkylthio, halo and nitro;
or a cycloalkyl selected from the group consisting of cyclohexyl and cyclopentyl;
ora pharmaceutically acceptable acid addition salt thereof, in a unit dosage form. - View Dependent Claims (12, 13, 14, 15, 16, 17, 18, 19, 20)
- administering to the subject in need thereof, a prophylactically effective amount of a compound of the formula;
Specification
-
- Resources
Litigation Campaign Assessment
Thank you for your request. You will receive a custom alert email when the Litigation Campaign Assessment is available.
×
-
Current AssigneeUpsher-Smith Laboratories Incorporated (SAWAI GROUP HOLDINGS Co., Ltd.)
-
Original AssigneeUpsher-Smith Laboratories Incorporated (SAWAI GROUP HOLDINGS Co., Ltd.)
-
InventorsLawyer, Carl H.
-
Primary Examiner(s)Reamer, James H.
-
Application NumberUS09/505,030Time in Patent Office629 DaysField of Search514/263, 514/264, 514/265US Class Current514/263.23CPC Class CodesA61K 31/52 Purines, e.g. adenine
